Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Kenvue Inc. Common Stock — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Kenvue Inc. Common Stock trades at $18.13 (market cap $34.11B). The key difference: Kenvue Inc. Common Stock is far larger — about 4× Hinge Health Inc. Class A Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.73% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Kenvue Inc. Common Stock for 1 Days on average.
| HNGE | KVUE | |
|---|---|---|
Market Cap | $8.48B | $34.11B |
Volume | 879,799 | 27,388,811 |
Sector | Health | Consumer Staples |
52-Week High | $105.14 | $19.83 |
52-Week Low | $31.17 | $14.11 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $8.10B | $41.62B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.
The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
